TL;DR
This study uses network pharmacology to identify active compounds in the traditional Chinese medicine formula Wenyang Jiedu Huayu (WYJDHY) that target acute-on-chronic liver failure (ACLF). They pinpointed atractylenolide I (AT-1) as a key compound and demonstrated its protective effects against ACLF in both cell cultures and animal models, primarily by inhibiting the NF-κB signaling pathway.
What Problem Does This Paper Address?
Acute-on-chronic liver failure (ACLF) is a severe condition characterized by rapid deterioration of liver function, massive cell death, and widespread inflammation, often leading to multiple organ failure and high mortality. While traditional Chinese medicine (TCM) has shown promise in treating ACLF, the specific active components and their mechanisms of action remain largely unclear. This study aims to bridge this knowledge gap by employing network pharmacology to predict the active ingredients of the WYJDHY formula and their therapeutic targets for ACLF, followed by experimental validation.
Methods
The researchers employed a multi-pronged approach:
- Network Pharmacology:
- Compound and Target Retrieval: They identified 23 active compounds from six herbs in the WYJDHY formula using the Traditional Chinese Medicine System Pharmacology Database (TCMSP) and PubChem, along with their associated drug targets.
- Disease Target Identification: ACLF-related genes were obtained from the GeneCards database.
- Co-target Analysis: Overlapping genes between drug targets and disease targets were identified.
- Differential Gene Expression Analysis: Publicly available gene expression data (GSE142255) for ACLF and normal samples was analyzed to identify differentially expressed genes (DEGs) among the co-targets.
- Functional Enrichment Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the identified DEGs to understand their biological functions and associated pathways.
- Network Construction: Protein-protein interaction (PPI) analysis was conducted using STRING, and herb-compound-signaling and herb-signaling-target networks were constructed using Cytoscape to identify key active ingredients and pathways.
- Experimental Validation:
- In Vitro Studies: Rat hepatocytes (BRL 3A cells) were treated with lipopolysaccharide (LPS) to induce an ACLF-like state. The effects of atractylenolide I (AT-1) and the NF-κB inhibitor PDTC, alone and in combination, were assessed on cell viability, apoptosis, liver function markers (ALT, AST), inflammatory cytokines (IL-6, VCAM-1), and the activation of the NF-κB signaling pathway (TLR4, p-p65).
- In Vivo Studies: An ACLF rat model was established. The therapeutic effects of AT-1, alone and in combination with PDTC, were evaluated on liver function (ALT, AST), liver histology, local inflammation (TLR4, p-p65), and immune cell populations (CD3+, CD4+, CD8+).
Datasets
- Compound and Target Data: TCMSP (http://lsp.nwu.edu.cn/tcmsp.php) and PubChem (https://pubchem.ncbi.nlm.nih.gov/).
- Disease Target Data: GeneCards.
- Gene Expression Data: GSE142255 from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142255).
Key Insights and Ideas
- Network Pharmacology as a Powerful Tool for TCM: The study effectively demonstrates how network pharmacology can untangle the complex mechanisms of multi-component TCM formulas, identifying key active ingredients and their targets.
- AT-1 as a Promising Candidate: Atractylenolide I (AT-1), derived from the herb BaiZhu, emerged as a central hub compound with significant potential for treating ACLF.
- NF-κB Pathway as a Critical Target: The research strongly implicates the NF-κB signaling pathway as a key mediator of ACLF pathogenesis and a crucial target for therapeutic intervention by AT-1.
- Synergistic Effects of AT-1 and NF-κB Inhibition: The combination of AT-1 and an NF-κB inhibitor (PDTC) showed enhanced protective effects, suggesting a potential for combination therapies.
- Multi-faceted Protective Mechanism: AT-1 appears to protect against ACLF by not only inhibiting the NF-κB pathway but also by reducing hepatocyte apoptosis, improving liver function markers, and modulating inflammatory responses.
Key Results
- Identification of 23 Active Compounds and 3,132 Co-targets: The network pharmacology analysis identified 23 active compounds from the WYJDHY formula and 3,132 overlapping targets between the formula and ACLF.
- 105 Differentially Expressed Genes (DEGs): Analysis of gene expression data revealed 105 DEGs among the co-targets, significantly associated with immune responses and pathways like Th17 cell differentiation and NF-κB signaling.
- AT-1 as a Hub Ingredient: Atractylenolide I (AT-1) was identified as a key active ingredient targeting the NF-κB pathway.
- In Vitro Efficacy of AT-1: AT-1 treatment significantly attenuated LPS-induced hepatocyte damage, reduced apoptosis, and lowered levels of ALT, AST, IL-6, and VCAM-1. It also inhibited the activation of the NF-κB pathway (TLR4 and p-p65 phosphorylation).
- Synergistic Effect of AT-1 and PDTC In Vitro: The combination of AT-1 and PDTC further enhanced the protective effects against LPS-induced toxicity.
- In Vivo Efficacy of AT-1: In ACLF model rats, AT-1 treatment (alone or with PDTC) improved liver function, reduced liver fibrosis and inflammation, and modulated immune cell populations. The combination therapy showed superior results.
Limitations and Future Work
- Limitations:
- The study primarily focused on AT-1 as the key compound. While other compounds were identified, their specific roles and interactions were not deeply explored.
- The study used a rat model for in vivo experiments, and further validation in other animal models or human studies would be beneficial.
- While the NF-κB pathway was identified as a primary target, other potential pathways and mechanisms of action for AT-1 may exist and warrant further investigation.
- Future Work:
- Investigate the synergistic effects of other active compounds within the WYJDHY formula.
- Explore the detailed molecular mechanisms by which AT-1 exerts its protective effects, including other signaling pathways.
- Conduct further preclinical and clinical studies to evaluate the therapeutic potential of AT-1 and the WYJDHY formula for ACLF.
Summary updated